Mean eDiary-assessed rescue medication use# during dosing periods (averaged across all 4-weekly dosing periods within the DREAM study)
| Dosing period | Placebo (n=155) | Mepolizumab | ||
| 75 mg (n=153) | 250 mg (n=152) | 750 mg (n=156) | ||
| First 2 weeks (days 1–14) | ||||
| n¶ | 152 | 151 | 151 | 154 |
| Mean (sd) | 2.0 (2.6) | 1.7 (2.8) | 2.0 (2.6) | 2.0 (2.7) |
| Second 2 weeks (days 15–28) | ||||
| n¶ | 152 | 151 | 151 | 154 |
| Mean (sd) | 2.1 (2.7) | 1.7 (2.9) | 2.0 (2.6) | 2.0 (2.8) |
| Mean change (sd) | 0.0 (0.3) | −0.0 (0.3) | −0.0 (0.3) | 0.0 (0.3) |
| ≥0 occasions per day increase | 73 (48%) | 68 (45%) | 70 (46%) | 75 (49%) |
| ≥1 occasion per day increase | 1 (<1%) | 2 (1%) | 1 (<1%) | 2 (1%) |
| ≥2 occasions per day increase | 0 | 0 | 0 | 1 (<1%) |
#: Daily rescue medication (short-acting β2-agonist) use included salbutamol and albuterol and was defined as occasions per day; ¶: patients with ≥7 days of eDiary data for both 2-week periods of at least one dosing interval were included in the analysis.